Cambridge Trust’s Indaptus Therapeutics INDP Stock Holding History

Cambridge Trust’s Portfolio INDP Stock Details INDP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-2	Closed	–	–	901
2022 Q1	$0	Buy	+2	New	+$257	﹤0.01%	1040

Other funds holding INDP

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

IHL

Investment House LLC Redondo Beach, California $1.92B AUM 25.81% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

SWP

Stratos Wealth Partners Beachwood, Ohio $8.8B AUM 21.82% 1-Year Est. Return

VCM

Vivaldi Capital Management Chicago, Illinois $723M AUM 30.89% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

HIIFS

Harel Insurance Investments & Financial Services Ramat Gan, Israel $14.7B AUM 47% 1-Year Est. Return

TRCT

Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return

Cambridge Trust's INDP Position: Q2 2022 in Review

Cambridge Trust sold out of Indaptus Therapeutics (INDP) in Q2 2022, closing a stake of 2 shares.

Cambridge Trust first reported a position in INDP in Q1 2022 and held it in 1 quarter. The position peaked at $0 in Q1 2022. 15 funds tracked by Wall St. Rank hold INDP as of Q2 2022.

Cambridge Trust reported no remaining Indaptus Therapeutics position as of Q2 2022 after selling out during the quarter.
Cambridge Trust sold 2 Indaptus Therapeutics shares in Q2 2022.
Cambridge Trust first reported a position in Indaptus Therapeutics in Q1 2022 and held it in 1 quarter.
Cambridge Trust's Indaptus Therapeutics position peaked at $0 in Q1 2022.
15 funds tracked by Wall St. Rank held Indaptus Therapeutics as of Q2 2022.

Based on Cambridge Trust's 13F filing for Q2 2022, filed 16 Aug 2022.